Billed as a health product, CBD faces stiff test from skeptical regulators

It’s marketed as a near-miraculous, over-the-counter pain reliever and health supplement—just how high can sales climb?

That’s the key question facing companies in the booming market for CBD (or cannabidiol), with cannabis and its derivatives making big strides toward nationwide legalization.

As regulators ramp up their scrutiny of the nascent industry, and officials in both major parties voice support for the marijuana-derived substance, a host of startups have increasingly emphasized the purported medical benefits of CBD.

The industry has hit its stride this year. While CBD comes from the same plant as its psychoactive brother, tetrahydrocannabinol (THC), CBD is billed as a non-psychoactive product that can reduce pain, anxiety, depression and act as a sleep aid.

The 2018 Farm Bill passed in December legalized

... read more at: https://finance.yahoo.com/news/cbd-faces-stiff-test-from-fda-as-cannabis-goes-mainstream-171703214.html